Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Jun 9, 2026, 11:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–37 of 13 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Intra-Abdominal Infection Clear all

Conditions: Complicated Intra-abdominal Infection
Interventions: CXA-201 and metronidazole, Meropenem; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Springfield, Illinois • Boston, Massachusetts • Robbinsdale, Minnesota + 1 more

Conditions: Complicated Intra-abdominal Infection
Interventions: TP-434, Ertapenem, Placebo; Drug
Lead sponsor: Tetraphase Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 5
States / cities: Long Beach, California • Denver, Colorado • Detroit, Michigan + 2 more

Conditions: Complicated Intra-abdominal Infections
Interventions: Ceftazidime -avibactam, Meropenem, Metronidazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 3 Months to 17 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Orange, California • San Diego, California • Toledo, Ohio + 1 more

Conditions: Bacterial Infections, Intra-Abdominal Infection, Pneumonia, Bacterial, Skin Diseases, Bacterial, Skin Diseases, Infectious
Interventions: Tygacil; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 8 Years to 11 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 18
States / cities: Long Beach, California • Oakland, California • Orange, California + 15 more

Conditions: Acute, Perforated Appendicitis
Interventions: Irrigation with PVI, Usual care; Drug · Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 2 Years to 17 Years
Enrollment: 1,750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Complicated Intra-abdominal Infections (cIAI)
Interventions: IV Eravacycline 2mg/kg, IV Eravacycline 1.5mg/kg; Drug
Lead sponsor: Tetraphase Pharmaceuticals, Inc; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • Chicago, Illinois + 2 more

Conditions: Pancreatic Trauma, Pancreatic Duct Injury, Pancreas Necrosis, Pancreas Cyst, Pancreas; Fistula, Pancreas Abscess, Intra-Abdominal Abscess, Anastomotic Leak, Pancreas Injury
Interventions: Exploratory laparotomy; Procedure
Lead sponsor: Kern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Bakersfield, California

Conditions: Intra Abdominal Infections
Interventions: Ertapenem, Sulopenem-Etzadroxil/Probenecid, Ciprofloxacin, Metronidazole, Amoxicillin-Clavulanate, Sulopenem; Drug
Lead sponsor: Iterum Therapeutics, International Limited; Industry
Eligibility: 18 Years and older
Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 12
States / cities: Chula Vista, California • Torrance, California • Idaho Falls, Idaho + 8 more

Conditions: Sepsis
Interventions: Frailty Measurements, Modified Minnesota Leisure Time Activities, Computed tomography morphometrics, Mobility Monitors; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Perforated Appendicitis
Interventions: PVI, Usual Care; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Respiratory Tract Infections, Urinary Tract Infections, Intra-Abdominal Infections, Skin and Soft Tissue Infection, Suspected Meningitis/Encephalitis or Any Other Infection, Sepsis
Interventions: TriVerity; Diagnostic Test
Lead sponsor: Inflammatix; Industry
Eligibility: 18 Years and older
Enrollment: 1,441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 25
States / cities: Mobile, Alabama • Los Angeles, California • Sacramento, California + 22 more

Conditions: Intra-abdominal Infections
Interventions: LYS228, Standard of care therapy; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Somers Point, New Jersey

Conditions: Abscess, Intra-Abdominal, Abdominal Abscess, Abdomen, Acute, Abdominal Pain, Appendicitis, Rupture, Infection, Intestinal Perforation, Peritonitis, Ileus
Interventions: Doripenem, Meropenem placebo, Meropenem, Doripenem placebo, Amoxicillin/clavulanate potassium; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 3 Months to 18 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 4
States / cities: San Diego, California • Washington D.C., District of Columbia • Cleveland, Ohio + 1 more

Search by objective public record fields.

Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections

Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections

Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).

Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age

Povidone-iodine Irrigation for Prevention of Intra-abdominal Abscess in Pediatric Perforated Appendicitis: a Multi-center Stepped Wedge Cluster Randomized Study

A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)

A Retrospective Analysis of Pancreatic Injuries and Treatment Outcomes

Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)

Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care and Induced Frailty

APPI-Cost Trial for Perforated Appendicitis

TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis

LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI)

A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections